Bayer and Loxo Oncology to develop and commercialize two novel oncology therapies selectively targeting genetic drivers of cancer (for specialized target groups only)

Larotrectinib (LOXO-101) and LOXO-195 target tropomyosin receptor kinase (TRK) fusion proteins, which are a product of genetic alterations that occur across a range of different tumors / Co-Promotion of the products in the U.S. / Bayer solely responsible for the commercialization of both products outside the U.S. / U.S. filing of larotrectinib planned for late 2017 or early 2018
Source: Bayer Company News - Category: Pharmaceuticals Source Type: news